Date of this Version
The paper in your April issue by Lai et al. entitled "Generation of cloned transgenic pigs rich in omega-3 fatty acids" (Nat. Biotechnol. 24, 435–436, 2006) perfectly captures the fundamental problem with American biotech research. That problem is that scientists pursue their research agenda to further scientific knowledge - all well and good - but when the project succeeds they invent problems for which their research results can be marketed as a solution. This unreflective move from 'pure science' to commercialization may end up as biotech's undoing.
Fiester, A. (2006). Why the Omega-3 Piggy Should Not Go to Market. Retrieved from https://repository.upenn.edu/bioethics_papers/54
Date Posted: 22 May 2007
This document has been peer reviewed.